Comvikin Biotechnology

Comvikin Biotechnology is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule immunomodulators for the treatment of cancer and chronic infectious diseases. The company leverages its proprietary technology platform to develop highly potent and selective agonists targeting innate immune pathways, such as Toll-like receptors (TLR7/8) and the STING pathway. Its lead programs are designed to activate the immune system to combat solid tumors and achieve functional cures for chronic Hepatitis B. Comvikin aims to provide transformative therapies by combining deep expertise in medicinal chemistry with advanced immunological insights.